References
Ricci F, Simone CD, Regno LD, Peris K. Drug-induced hair colour changes. Eur J Dermatol 2016; 26: 531–6.
Osio A, Battistella M, Feugeas J-P, et al. Myelodysplasia cutis versus leukemia cutis. J Invest Dermatol 2015; 135: 2321–4.
Farah C, Bulai Livideanu C, Jegu J, et al. Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. J Eur Acad Dermatol Venereol 2010; 24: 1171–5.
Doll DC, Kasper LM, Taetle R, List AF. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. Leuk Res 1998; 22: 7–12.
Avivi I, Rosenbaum H, Levy Y, Rowe J. Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res 1999; 23: 323–30.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rioli, DI., Walter, A., Puyade, M. et al. Efficacy of etoposide for myelodysplasia cutis. Eur J Dermatol 28, 246–247 (2018). https://doi.org/10.1684/ejd.2018.3225
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2018.3225